BIND Therapeutics, Inc.(BIND)- NASDAQ
  • Wed, Aug. 31, 12:42 PM
    | Wed, Aug. 31, 12:42 PM | 20 Comments
  • Fri, Jul. 1, 6:28 PM
    • Bankrupt BIND Therapeutics (NASDAQ:BIND) has doubled in price after hours, +101%, after filing a motion to sell the majority of its assets into a stalking-horse bid from Pfizer (NYSE:PFE).
    • Pfizer's agreed to acquire substantially all the assets of the company for about $20M in cash, and had presented the initial stalking-horse bid as BIND filed for Chapter 11 bankruptcy on May 1.
    • BIND has asked the bankruptcy court for authorization to proceed with a July 25 auction, with a completed transaction expected in Q3.
    • Update: Two other bidders will participate in auction of BIND's assets on July 25 at 10:00 am ET.
    • Update: On July 26, BIND announced that Pfizer prevailed with a bid of $40M. NanoCarrier Co., Ltd. was selected as the back-up bidder.
    | Fri, Jul. 1, 6:28 PM | 45 Comments
  • Mon, May 9, 7:05 AM
    • BIND Therapeutic (NASDAQ:BIND): Q1 EPS of -$0.61 misses by $0.06.
    • Revenue of $1.87M (-57.3% Y/Y) misses by $1.96M.
    • Press Release
    | Mon, May 9, 7:05 AM
  • Thu, May 5, 1:22 PM
    • Thinly traded nano cap BIND Therapeutics (BIND +34.9%) heads north on a healthy 27x surge in volume in response to its announcement that it has entered into a research collaboration with privately-held French biotech Affilogic, a developer of affinity proteins called Nanofitins that selectively bind to very specific targets.
    • Under the terms of the partnership, BIND will use Nanofitins as targeting ligand components for ACCURINS in immuno-oncology. After the proof-of-concept stage, BIND expects to expand the collaboration to develop ACCURINS that incorporate unique targeting ligands and new classes of payloads, including oligonucleotides and molecularly targeted therapies. Financial details are not disclosed.
    • ACCURINS are nanoparticles that incorporate a therapeutic payload and are designed to have prolonged circulation in the bloodstream thereby providing controlled and timely release of the therapy to diseased tissue or cells.
    | Thu, May 5, 1:22 PM | 10 Comments
  • Mon, May 2, 12:47 PM
    | Mon, May 2, 12:47 PM | 3 Comments
  • Mon, May 2, 9:13 AM
    | Mon, May 2, 9:13 AM | 4 Comments
  • Mon, May 2, 6:55 AM
    • BIND Therapeutics (NASDAQ:BIND) files for protection under Chapter 11 of the U.S. Bankruptcy Code after it received a notice of default from lender Hercules Technology III, L.P. in April 26 related to a $15M credit facility. The companies failed to reach an agreement on restructuring the debt, which stood at $13.2M on May 1. The company's filing was triggered by Hercules' insistence that $14.5M (debt, attorneys fees, late fees and costs of collection) be immediately repaid, which it believed to not be in its best interests. Hercules also says the interest will accrue at a rate of ~$3,166 per day.
    • The lender alleges that BIND failed to deliver a control agreement related to one of its investment accounts which violated the terms of the credit facility and constituted a default.
    • BIND is down 24% premarket but only on 200 shares.
    • Update: On May 19, the company reported that it reached agreement with Hercules for the use of cash collateral through July 8 subject to conditions. It also agreed to pay down $4M on the existing principal loan balance of ~$12.4M.
    | Mon, May 2, 6:55 AM
  • Fri, Apr. 8, 11:05 AM
    • MacroGenics (MGNX +3.1%) initiated with Buy rating and $35 price target by BTIG Research.
    • Viking Therapeutics (VKTX -39.4%) initiated with Buy rating and $6 price target by H.C. Wainwright.
    • Pfizer (PFE -0.3%) initiated with an Overweight rating and $38 price target by JP Morgan.
    • Medivation (MDVN -0.1%) initiated with Buy rating and $56 price target by SunTrust Robinson Humphrey.
    • Eyegate Pharmaceuticals (EYEG +6.5%) initiated with Buy rating and $10 price target by Noble Financial.
    • Eiger Biopharmaceuticals (EIGR +0.5%) initiated with Buy rating and $35 price target by Jefferies.
    • Vertex Pharmaceuticals (VRTX +0.3%) initiated with Market Perform rating and a $90 price target by BMO Capital.
    • SocGen has been busy with initiations on six large cap pharmas: Buy: Merck (MRK +0.1%); Hold: Johnson & Johnson (JNJ -0.4%), Eli Lilly (LLY -0.3%) and Pfizer; Sell: Bristol-Myers Squibb (BMY -0.4%) and AbbVie (ABBV -0.9%).
    • Tokai Pharmaceuticals (TKAI -6.7%) initiated with Buy rating and $16 price target by Bank of America. Initiated with Buy rating by Janney Capital.
    • Cellectis (CLLS -0.1%) initiated with Buy rating and $45 price target by Ladenburg Thalmann.
    • Novartis (NVS +0.5%) initiated with Hold rating by Argus Research.
    • TherapeuticsMD (TXMD) initiated with Buy rating and $10 price target by Goldman Sachs.
    • Protalix (PLX -4.2%) initiated with Buy rating and $3.50 price target by Rodman & Renshaw.
    • Raptor Pharmaceuticals (RPTP -0.4%) upgraded to Outperform from Market Perform by JMP Securities.
    • Ironwood Pharmaceuticals (IRWD -0.6%) upgraded to Outperform from Market Perform by Cowen & Company. Price target raised to $16 from $12.
    • Intercept Pharmaceuticals (ICPT -6%) upgraded to Outperform from Market Perform by Wells Fargo.
    • Edwards Lifesciences (EW -0.1%) upgraded to Buy from Neutral with $115 price target by BTIG Research.
    • Express Scripts (ESRX +0.7%) upgraded to Outperform from Market Perform by Cowen & Company. Price target raised to $80 from $76.
    • BIND Therapeutics (BIND -7%) downgraded to Market Perform from Outperform by Cowen & Company.
    • Allergan (AGN -0.5%) downgraded to Neutral from Buy by Mizuho Securities. Downgraded to Neutral from Positive by Susquehanna. Price target lowered to $275 from $345.
    • Bruker (BRKR +0.2%) downgraded to Market Perform from Outperform by Leerink Swann. Price target is $27.
    | Fri, Apr. 8, 11:05 AM | 9 Comments
  • Wed, Apr. 6, 12:46 PM
    | Wed, Apr. 6, 12:46 PM
  • Wed, Apr. 6, 10:43 AM
    • Thinly traded nano cap BIND Therapeutics (BIND -26.2%) slumps on almost triple normal volume, albeit on turnover of only ~210K shares, in response to its announcement that it will cut 38% of its employees by the end of the month in order to reduce operating costs. It also plans to assess its options regarding its wholly owned subsidiary in Moscow.
    • The move was prompted by a shift in R&D strategy and by less-than-hoped-for results from two Phase 2 studies of lead product candidate BIND-014, an ACCURIN drug candidate containing the chemo agent docetaxel.
    • The first trial, called iNSITE 1, evaluated BIND-014 in advanced non-small cell lung cancer. The primary endpoint was the disease control rate (DCR), which includes total responders, partial responders and those with stable disease (no progression). BIND-014 showed a 52.5% DCR at week 6 in the intent-to-treat population and 70.0% in the per-protocol population, below and above the protocol-defined threshold for success of 65.0%. The company intends to seek licensing or collaboration deals for the further development for the indication.
    • The second, iNSITE 2, was assessing BIND-014 in advanced cervical and head and neck cancers. In the first stage, the objective response rate was only 10% for the head and neck cohort and 0% for the cervical group. As a result, the company has stopped enrollment.
    • The company will continue its development and collaboration activities in line with its innovative medicines strategy, specifically, transitioning the company from a technology platform business to one focused on leveraging the benefits of ACCURINS to maximize the clinical benefits for patients.
    • ACCURINS are nanoparticles that incorporate a therapeutic payload and are designed to have prolonged circulation in the bloodstream thereby providing controlled and timely release of the therapy to diseased tissue or cells.
    • Read now It's Time To Invest In BIND Therapeutics 
    | Wed, Apr. 6, 10:43 AM
  • Tue, Mar. 15, 10:05 AM
    • BIND Therapeutic (BIND) Q4 results: Revenues: $6.4M (+113.3%); R&D Expense: $11.1M (+38.8%); SG&A: $4.6M (+9.5%); Operating Loss: ($9.3M) (-1.1%); Net Loss: ($7.6M) (+10.6%); Loss Per Share: ($0.37) (+27.5%).
    • FY2015 results: Revenues: $15.4M (+48.1%); R&D Expense: $37.3M (+29.1%); SG&A: $17.6M (+16.6%); Operating Loss: ($39.5M) (-17.9%); Net Loss: ($36.6M) (-12.6%); Loss Per Share: ($1.81) (+8.1%); Quick Assets: $36.9M (-9.8%).
    • No guidance given.
    | Tue, Mar. 15, 10:05 AM
  • Tue, Mar. 15, 7:02 AM
    • BIND Therapeutic (NASDAQ:BIND): Q4 EPS of -$0.37 beats by $0.12.
    • Revenue of $6.42M (+111.2% Y/Y) beats by $3.07M.
    | Tue, Mar. 15, 7:02 AM
  • Mon, Mar. 14, 5:43 PM
    | Mon, Mar. 14, 5:43 PM | 2 Comments
  • Tue, Feb. 16, 12:16 PM
    • With the aim of developing new treatments for certain gastrointestinal (GI) cancers, BIND Therapeutics (BIND -0.7%) and Synergy Pharmaceuticals (SGYP +3.6%) ink a research collaboration to engineer BIND's ACCURINS incorporating Synergy's uroguanylin analogs. The research will target GI tumors that express guanylate cyclase-C (GC-C) receptors.
    • If the proof-of-concept is successful, the companies intend to expand their partnership by incorporating therapeutic payloads into uroguanylin-based ACCURINS in order to enhance their efficacy.
    • Financial terms of the collaboration are not disclosed.
    • Uroguanylin is a naturally occurring GI peptide that activates the intestinal GC-C receptor.
    • ACCURINS are nanoparticles that incorporate a therapeutic payload and are designed to have prolonged circulation in the bloodstream thereby providing controlled and timely release of the therapy to diseased tissue or cells.
    | Tue, Feb. 16, 12:16 PM | 11 Comments
  • Thu, Jan. 7, 12:35 PM
    • A Phase 2 clinical trial assessing BIND Therapeutics' (BIND -1.4%) investigational BIND-014, an ACCURIN drug candidate containing the chemo agent docetaxel, in patients with chemo-naive metastatic castration-resistant prostate cancer (mCRPC) met its primary efficacy endpoint with 71% of patients achieving radiographic progression-free survival (rPFS) for at least six months. The data were presented today at the 2016 Genitourinary Cancers Symposium in San Francisco.
    • Despite the encouraging results, the company is terminating further development of BIND-014 for mCRPC, preferring to focus its resources on non-small cell lung cancer (the Phase 2 iNSITE 1 trial) and multiple tumor types (urothelial carcinoma, cholangiocarcinoma, cervical cancer, squamous cell carcinoma of the head and neck)(the Phase 2 iNSITE 2 trial).
    | Thu, Jan. 7, 12:35 PM
  • Dec. 14, 2015, 12:44 PM
    | Dec. 14, 2015, 12:44 PM